Evaluation of TP53 Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic TP53 Variants ( vol 5 , 2021 , 10.1200/PO.21.00278)

被引：0
|
作者：
Cahill, Sophie R.
机构：
来源：
JCO PRECISION ONCOLOGY | 2023年 / 7卷
关键词：
D O I：
10.1200/PO.23.00501
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 25 条
  • [21] TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutations
    Ghezelayagh, Talayeh S.
    Kohrn, Brendan F.
    Fredrickson, Jeanne
    Krimmel-Morrison, Jeffrey D.
    Latorre-Esteves, Elena
    Tee, Xin-Ray
    Radke, Marc R.
    Manhardt, Enna
    Norquist, Barbara M.
    Katz, Ronit
    Swisher, Elizabeth M.
    Risques, Rosa Ana
    ONCOGENE, 2024, 43 (31) : 2421 - 2430
  • [22] Results from London Regional Clinical Genetics services over a 5-year period on germline TP53 testing in women diagnosed with breast cancer at <30 years
    Garrett, Alice
    Talukdar, Sabrina
    Izatt, Louise
    Brady, Angela F.
    Whyte, Sinead
    Josephs, Katherine S.
    Shanmugasundaram, Monisha
    Guillemot, Li Shan
    Vakili, Dara
    Ey, Shevaun
    Ahmed, Munaza
    JOURNAL OF MEDICAL GENETICS, 2022, 59 (06) : 554 - 558
  • [23] Genetic Testing of Breast Cancer Patients with Very Early-Onset Breast Cancer (≤30 Years) Yields a High Rate of Germline Pathogenic Variants, Mainly in the BRCA1, TP53, and BRCA2 Genes
    Apostolou, Paraskevi
    Dellatola, Vasiliki
    Papathanasiou, Athanasios
    Kalfakakou, Despoina
    Fountzilas, Elena
    Tryfonopoulos, Dimitrios
    Karageorgopoulou, Sofia
    Yannoukakos, Drakoulis
    Konstantopoulou, Irene
    Fostira, Florentia
    CANCERS, 2024, 16 (13)
  • [24] Effect of the codon 72 polymorphism (c.215G > C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma (vol 24, pg 21, 2004)
    Wang, Y
    Kringen, P
    Kristensen, GB
    Holm, R
    Baekelandt, MMO
    Olivier, M
    Skomedal, H
    Hainaut, P
    Tropé, CG
    Abeler, VM
    Nesland, JM
    Borresen-Dale, AL
    Helland, Å
    HUMAN MUTATION, 2006, 27 (02) : 209 - 210
  • [25] Author's Response to: Comment on "Impact of EML4-ALK Variants and Co- Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion- Positive NSCLC: Real-World Outcomes From the GuardantINFORM Database" and "Critical Evaluation of Methodological Approaches in ALK TKI Research: Addressing Confounding Factors and Statistical Robustness"
    Parikh, Kaushal
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (11) : e66 - e67
123